title: Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis.
abstract: We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20-29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24-14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.
authors.affiliation: Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan, k.ohashi@cick.jp.
authors.forename: Kazuteru
authors.initials: K
authors.lastname: Ohashi
authors.forename: Tokiko
authors.initials: T
authors.lastname: Nagamura-Inoue
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Nagamura
authors.forename: Arinobu
authors.initials: A
authors.lastname: Tojo
authors.forename: Kouichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Takehiko
authors.initials: T
authors.lastname: Mori
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
authors.forename: Shuichi
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Jun
authors.initials: J
authors.lastname: Ishikawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Atsuta
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D036102:Peripheral Blood Stem Cell Transplantation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D061349:Unrelated Donors
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
references.citation: Bone Marrow Transplant. 2001 Apr;27(7):693-701
references.pmid: 11360108
references.citation: Bone Marrow Transplant. 2010 Nov;45(11):1579-86
references.pmid: 20531284
references.citation: Biol Blood Marrow Transplant. 2005 Feb;11(2):85-92
references.pmid: 15682068
references.citation: Cancer Cell. 2009 Nov 6;16(5):401-12
references.pmid: 19878872
references.citation: N Engl J Med. 1998 Nov 26;339(22):1565-77
references.pmid: 9828244
references.citation: Blood. 2010 Mar 11;115(10):1880-5
references.pmid: 19965667
references.citation: Haematologica. 2006 Aug;91(8):1145-6
references.pmid: 16870551
references.citation: Blood. 2012 Aug 16;120(7):1390-7
references.pmid: 22613793
references.citation: Haematologica. 2006 Apr;91(4):513-21
references.pmid: 16533723
references.citation: Br J Haematol. 2007 Jun;137(5):461-7
references.pmid: 17459051
references.citation: Blood. 2007 Feb 15;109(4):1782-9
references.pmid: 17062727
references.citation: Haematologica. 2006 Apr;91(4):452-9
references.pmid: 16585011
references.citation: N Engl J Med. 2012 Nov 29;367(22):2075-88
references.pmid: 23190221
references.citation: Int J Hematol. 2007 Oct;86(3):269-74
references.pmid: 17988995
references.citation: Int J Hematol. 2013 Sep;98(3):300-8
references.pmid: 23893313
references.citation: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references.pmid: 19884523
references.citation: Blood. 2008 Oct 15;112(8):3500-7
references.pmid: 18664621
references.citation: Semin Hematol. 2010 Oct;47(4):354-61
references.pmid: 20875552
references.citation: Bone Marrow Transplant. 1995 Jun;15(6):825-8
references.pmid: 7581076
references.citation: Blood. 2007 Jun 1;109(11):4686-92
references.pmid: 17317858
references.citation: Semin Hematol. 1991 Jul;28(3):250-9
references.pmid: 1887253
references.citation: Blood. 2000 Jun 15;95(12):3702-9
references.pmid: 10845900
references.citation: Bone Marrow Transplant. 2008 Aug;42(4):241-51
references.pmid: 18574449
references.citation: Bone Marrow Transplant. 2012 Jun;47(6):810-6
references.pmid: 21986636
references.citation: N Engl J Med. 1997 Aug 7;337(6):373-81
references.pmid: 9241126